BarnesDWMoleRH. Allogeneic lymphoid cell disease in midlethally irradiated CBA mice: The delayed harmful effects of small numbers of C3H lymphoid cells. Int J Radiat Biol Relat Stud Phys Chem Med1969; 15:43–50.
2.
RembergerMRingdenOBlauIW. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood2001; 98:1739–1745.
3.
BeattyPGHansenJALongtonGM. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation1991; 51:443–447.
4.
StorekJGooleyTSiadakM. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood1997; 90:4705–4709.
5.
GazievDPolchiPGalimbertiM. Graft-versus-host disease after bone marrow transplantation for thalassemia: An analysis of incidence and risk factors. Transplantation1997; 63:854–860.
6.
LazarusHMRoweJM. New and experimental therapies for treating graft-versus-host disease. Blood Rev1995; 9:117–133.
7.
Urbano–IspizuaAGarcia–CondeJBrunetS. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT. Haematologica1997; 82:683–689.
8.
RatanatharathornVAyashLLazarusHM. Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant2001; 28:121–129.
9.
VogelsangGB. How I treat chronic graft-versus-host disease. Blood2001;97:1196–1201.
10.
ShulmanHMSaleGELernerKG. Chronic cutaneous graft-versus-host disease in man. Am J Pathol1978; 91:545–570.
11.
EppingerTEhningerGSteinertM. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation1990; 50:807–811.
12.
AubinFBrionADeconinckE. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. Transplantation1995; 59:151–155.
VogelsangGBWolffDAltomonteV. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant1996; 17:1061–1067.
15.
BasaraNGunzelmannSWillenbacherW. New immunosuppressants in BMT/GVHD. Transplant Proc2001; 33:2220–2222.
16.
SimpsonD. Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res2000; 9:317–325.
17.
PrzepiorkaDKernanNAIppolitiC. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood2000; 95:83–89.
18.
VogelsangGBFarmerERHessAD. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med1992; 326:1055–1058.
19.
SastryPSPowlesRI. Thalidomide for chronic GVHD. Bone Marrow Transplant1998; 22:933–934.
20.
NestelFPPriceKSSeemayerTA. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med1992; 175:405–413.
21.
AbhyankarSGillilandDGFerraraJL. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation1993; 56:1518–1523.
22.
TanakaJImamuraMKasaiM. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant1997; 19:571–576.
23.
LuYSakamakiSKurodaH. Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603. Blood2001; 97:1123–1130.
24.
FowlerDHGressRE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma2000; 38:221–234.
25.
FerraraJLAbhyankarSGillilandDG. Cytokine storm of graft-versus-host disease: A critical effector role for interleukin-1. Transplant Proc1993; 25:1216–1217.
26.
FerraraJL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol1993; 5:794–799.
27.
KorholzDKunstDHempelL. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant1997; 19:691–695.
28.
BladonJTaylorPC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol1999; 107:707–711.
29.
BergerCLXuALHanlonD. Induction of human tumor-loaded dendritic cells. Int J Cancer2001; 91:438–447.
30.
RookAHFreundlichBJegasothyBV. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol1992; 128:337–346.
31.
DeegHJGrahamTCGerhard-MillerL. Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation. Blood1989; 74:2592–2595.
32.
TruittRLJohnsonBDHankeC. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol1999; 163:5145–5156.
33.
VinkAAMoodycliffeAMShreedharV. The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc Natl Acad Sci USA1997; 94:5255–5260.
34.
OwsianowskiMGollnickHSiegertW. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant1994; 14:845–848.
35.
RossettiFZulianFDall'AmicoR. Extracorporeal photochemotherapy as single therapy for expensive, cutaneous, chronic graft-versus-host disease. Transplantation1995; 59:149–151.
36.
RossettiFDall'AmicoRCrovettiG. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant1996; 18Suppl 2:175–181.
37.
Dall'AmicoRRossettiFZulianF. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol1997; 97:848–854.
38.
ChildFJRatnavelRWatkinsP. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant1999; 23:881–887.
39.
GreinixHTVolc–PlatzerBRabitschW. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood1998; 92:3098–3104.
40.
GreinixHTVolc–PlatzerBKalhsP. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study. Blood2000; 96:2426–2431.
41.
AlcindorTGorgunGMillerKB. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood2001; 98:1622–1625.
42.
GorgunGMillerKBFossFM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood2002; 100:941–947.
43.
ShlomchikWDCouzensMSTangCB. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science1999; 285:412–415.
44.
ChanGWChanGGorgunGMillerKB. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant2003; 9:170–176.
